Interní Med. 2017; 19(3): 162-166 | DOI: 10.36290/int.2017.051

A single-centre experience of antifibrotic treatment in idiopathic pulmonary fibrosis

MUDr. Monika Žurková, Ph.D.¹, MUDr. Filip Čtvrtlík, Ph.D.², MUDr. Vladimíra Loštáková, Ph.D.¹, MUDr. Tomáš Tichý, Ph.D.³, Dr. Eva Kriegová⁴

1Klinika plicních nemocí a tuberkulózy FN a LF UP Olomouc

2Radiologická klinika FN a LF UP Olomouc

3Ústav patologie LF a UP Olomouc

4Ústav imunologie LF a UP Olomouc

Idiopathic pulmonary fibrosis (IPF) is one of the most difficult to treat diseases with usually progressive course and unfavourable prognosis.

Together with development of new therapeutic approaches there is a need to early diagnose this disease. With early diagnosis more

patients are able to receive new types of antifibrotic drugs. In our current clinical practice, we may choose two different treatments – pirfenidone

(2 403 mg/day, i. e. 3 × 3 cps) or nintedanib (300 mg/day, i. e. 2 × 1 tbl.). Here we present a case report of 69 years old patient with

diagnosis of IPF who was treated with antifibrotic therapy (pirfenidone) which led to complete stabilization of pulmonary impairment.

Keywords: idiopathic pulmonary fibrosis, antifibrotic therapy, pirfenidone, nintedanib

Received: February 1, 2018; Accepted: April 17, 2018; Prepublished online: April 17, 2018; Published: July 1, 2017  Show citation